Andrew Emili

Andrew Emili is a Professor at Oregon Health & Science University, where he leads a high-profile research program in systems biology and proteomics. His work integrates molecular biology, genetics, and pharmacology to map protein interaction networks, with recent emphasis on protein-phospholipid dynamics in cancer, transcription factor ligand landscapes in E. coli, and proximity labeling technologies for cell-surface receptor mapping. His latest breakthroughs include a chemo-omic pipeline identifying prion synaptotoxic pathways and inhibitory drugs, alongside translational studies on empagliflozin’s metabolic effects in hypertrophic cardiomyopathy. He has secured major funding, including a CAD 135,268 award for a Proteomic Facility for Biomarker Discovery, and collaborates internationally across diverse model systems, from Drosophila oogenesis to symbiotic corals.